(1R,2S,10R,12R,13S)-10-(aminomethyl)-8,19-dihydroxy-5,7,16,18-tetramethoxy-6,17,21-trimethyl-11,21-diazapentacyclo[11.7.1.02,11.04,9.015,20]henicosa-4(9),5,7,15(20),16,18-hexaene-12-carbonitrile | 349103-35-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (1R,2S,10R,12R,13S)-10-(aminomethyl)-8,19-dihydroxy-5,7,16,18-tetramethoxy-6,17,21-trimethyl-11,21-diazapentacyclo[11.7.1.02,11.04,9.015,20]henicosa-4(9),5,7,15(20),16,18-hexaene-12-carbonitrile
• CAS: 349103-35-1
• 化学式: C₂₈H₃₆N₄O₆
• 分子量: 524.617
• InChiKey: WDIFOQIUNXWDFM-SHUHUVMISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  38
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  134
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  (1R,2S,10R,12R,13S)-10-(aminomethyl)-8,19-dihydroxy-5,7,16,18-tetramethoxy-6,17,21-trimethyl-11,21-diazapentacyclo[11.7.1.02,11.04,9.015,20]henicosa-4(9),5,7,15(20),16,18-hexaene-12-carbonitrile 在 亚碘酰苯 、 N,N-二乙基苯胺 作用下， 以 二氯甲烷 、 水 、 乙腈 为溶剂， 生成 沙弗拉霉素 A
  参考文献：
  名称：

  A Concise, Stereocontrolled Synthesis of (−)-Saframycin A by the Directed Condensation of α-Amino Aldehyde Precursors

  摘要：

  DOI：

  10.1021/ja993079k
• 作为产物：
  描述：

  9H-fluoren-9-ylmethyl N-[[(1R,2S,10R,12R,13S)-12-cyano-8,19-dihydroxy-5,7,16,18-tetramethoxy-6,17,21-trimethyl-11,21-diazapentacyclo[11.7.1.02,11.04,9.015,20]henicosa-4(9),5,7,15(20),16,18-hexaen-10-yl]methyl]carbamate 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 为溶剂， 以88%的产率得到(1R,2S,10R,12R,13S)-10-(aminomethyl)-8,19-dihydroxy-5,7,16,18-tetramethoxy-6,17,21-trimethyl-11,21-diazapentacyclo[11.7.1.02,11.04,9.015,20]henicosa-4(9),5,7,15(20),16,18-hexaene-12-carbonitrile
  参考文献：
  名称：

  A Concise, Stereocontrolled Synthesis of (−)-Saframycin A by the Directed Condensation of α-Amino Aldehyde Precursors

  摘要：

  DOI：

  10.1021/ja993079k

文献信息

• Saframycins, analogues and uses thereof
  申请人：Myers G. Andrew

  公开号：US20070112008A1

  公开（公告）日：2007-05-17

  In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I), and methods for the synthesis thereof. In another aspect, the present invention provides pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. In yet another aspect, the present invention provides methods for treating cancer comprising administering a therapeutically effective amount of a compound of formula (I) to a subject in need thereof.

  为了开发新型治疗剂和有效的合成方法，本发明提供了一般式(I)的新化合物及其合成方法。在另一个方面，本发明提供了含有式(I)化合物和药学上可接受的载体的制药组合物。在另一个方面，本发明提供了治疗癌症的方法，包括向需要治疗的受体施用化合物(I)的治疗有效量。
• [EN] SAFRAMYCIN ANALOGS AS THERAPEUTIC AGENTS IN THE TREATMENT OF CANCER<br/>[FR] NOUVEAUX ANALOGUES DE SAFRAMYCINE UTILISES EN TANT QU'AGENTS THERAPEUTIQUES
  申请人：AXYS PHARM INC

  公开号：WO2005118584A3

  公开（公告）日：2006-03-23
• Total synthesis of (.+-.)-saframycin A
  作者：Tohru Fukuyama、Lihu Yang、Karen L. Ajeck、Richard A. Sachleben

  DOI：10.1021/ja00165a095

  日期：1990.4
• Synthesis and Evaluation of Bishydroquinone Derivatives of (−)-Saframycin A:  Identification of a Versatile Molecular Template Imparting Potent Antiproliferative Activity
  作者：Andrew G. Myers、Alleyn T. Plowright

  DOI：10.1021/ja0103086

  日期：2001.5.1
• Evaluation of antitumor properties of novel saframycin analogs in vitro and in vivo
  作者：Jeffrey R. Spencer、Martin Sendzik、Jason Oeh、Peter Sabbatini、Stacie A. Dalrymple、Catherine Magill、Hyunjin M. Kim、Penglie Zhang、Neil Squires、Katherine G. Moss、Juthamas Sukbuntherng、Doris Graupe、John Eksterowicz、Peter R. Young、Andrew G. Myers、Michael J. Green

  DOI：10.1016/j.bmcl.2006.06.085

  日期：2006.9

  Novel analogs of (-)-saframycin A are described. The analogs are shown to be potent inhibitors of the in vitro growth of several tumor cells in a broad panel and promising as leads for further optimization. The first in vivo studies in a solid tumor model (HCT-116) reveal potent antitumor activity with associated toxicity of daily administration. (c) 2006 Elsevier Ltd. All rights reserved.